GENEART AG and Applied Biosystems Deutschland GmbH intend to conclude a domination agreement
GENEART AG and its majority shareholder, Applied Biosystems Deutschland GmbH, intend to conclude a domination agreement pursuant to Section 291 et seq. German Stock Corporation Act (Aktiengesetz) with GENEART AG as the dominated entity and Applied Biosystems Deutschland GmbH as the dominating entity. GENEART AG and Applied Biosystems Deutschland GmbH want to execute such agreement before GENEART AG's annual general meeting scheduled for August 19, 2010. The domination agreement shall be submitted for approval to GENEART AG's general meeting in the context of the company's annual general meeting scheduled for August 19, 2010.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
Roche and RainDance Technologies Join Forces in Targeted Sequencing to Advance ADME Research - Collaboration to enable scientists to capture known and unknown functional mutations associated with core set of pharmacokinetic and pharmacology genes
CHEMIE.DE gives technological support for the launch of a food and beverages internet portal - The new B2B web portal yumda.de builds on the proven technology of Europe's leading chemistry portal
OctoPlus wins drug development and manufacturing contract from Danish pharmaceutical company
